Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Health

The age limit moved from 12 to five, and for some families that changes everything

Qurexa Editorial Team4 November 20266 min read 0 0
The age limit moved from 12 to five, and for some families that changes everything

What happened

On 30 October 2026, the MHRA announced that it has extended the UK licence for a gene-editing treatment called Casgevy. The medicine's full name is exagamglogene autotemcel. Until now, Casgevy could only be given in the UK to patients aged 12 and over. The licence extension, which was granted on 29 October 2026 to Vertex Pharmaceuticals, means eligible children aged five and over can now be treated too. It applies to two serious inherited blood conditions: severe sickle cell disease, and transfusion-dependent beta-thalassaemia. Julian Beach, the MHRA's Executive Director of Operations, said both conditions are "serious, lifelong conditions that in some cases can be fatal", and that the decision was based on "careful assessment of the available evidence on the treatment's safety, quality and effectiveness". On the question of NHS funding, NICE has also acted. Rather than running a whole new appraisal, NICE concluded that it could update its existing recommendation to include children aged 5 to 11, and published a managed access agreement. NICE's reasoning was that extending the recommendation to younger patients would not substantially change the main uncertainties it had already identified when it looked at the 12-and-over group. Casgevy was first approved in the UK in November 2023.

Why this matters

To see why the age change matters, it helps to know what these two conditions do. Both are caused by faults in the genes for haemoglobin. Haemoglobin is the substance in red blood cells that carries oxygen around your body. In severe sickle cell disease, that fault can cause attacks of very severe pain, serious and life-threatening infections, and anaemia, which means the body struggles to carry oxygen properly. In beta-thalassaemia, the main problem is severe anaemia. The MHRA notes that patients often need a blood transfusion every three to five weeks, plus injections and medicines for life. Read that again: a transfusion every three to five weeks, for life. For a child, that is school missed, trips cancelled, and a hospital appointment that never stops coming round. Sickle cell disease in the UK affects a large number of people of Black African and Black Caribbean heritage in particular, and families have campaigned for years about how slowly new options have arrived. Moving the age limit from 12 down to five means children can potentially be treated before more of those years go by.

What the evidence actually says

Casgevy is not a tablet or an injection you simply take. It is a one-off procedure, and it is a demanding one. Here is how it works. Doctors collect blood stem cells from the patient's own bone marrow. In a laboratory, a gene-editing tool is used to change a faulty gene in those cells so the body starts producing working haemoglobin again. The edited cells are then put back into the patient. Before that can happen, the patient has what is called conditioning treatment. This clears space in the bone marrow for the edited cells. After the infusion, the MHRA says patients may need to stay in hospital while the treated cells settle into the bone marrow and start making red blood cells. There are side effects. The MHRA lists nausea, tiredness, fever and an increased risk of infection. It is also important to be clear about what this approval is and is not. A licence extension means the regulator is satisfied the treatment can be used safely and effectively in this age group. It does not mean every child with these conditions will be offered it, or offered it quickly. Treatment like this happens at a small number of specialist centres. Patients have to meet eligibility criteria. The practical history here is instructive: for the 12-and-over group, there was a gap of many months between MHRA approval and the treatment actually being available on the NHS. Some reporting has pointed out that families of younger children should not expect same-day access, while Vertex and NICE describe the funding route as now in place. The realistic reading is that the regulatory and funding doors are now open for 5 to 11-year-olds, and that how fast families walk through them depends on specialist capacity and individual eligibility. The place to get a real answer is a child's own specialist team.

Practical advice

If your child has severe sickle cell disease or transfusion-dependent beta-thalassaemia, the person to speak to is the haematology team that already looks after them. They will know the referral routes and whether your child fits the eligibility criteria. It is reasonable to ask direct questions. Is my child eligible? Which centre would we go to? What is the realistic waiting time? What does the conditioning treatment involve, and how long would we be in hospital? Ask about the trade-offs too. This is a serious procedure with real side effects, and for some families the right answer will be to carry on with current care. That is a legitimate choice, not a failure. If you are not already under a specialist team, start with your GP and ask for a referral. For families living with these conditions day to day, the ordinary things still matter while all this is being worked out. Keep up with vaccinations, because infection risk is higher in sickle cell disease. Keep existing medicines going as prescribed. Keep transfusion appointments. UK charities that support people with these conditions, including the Sickle Cell Society and the UK Thalassaemia Society, can be useful for talking to other families who have been through the decision.

What to know

The MHRA has extended Casgevy's UK licence from age 12 down to age five, for eligible children with severe sickle cell disease or transfusion-dependent beta-thalassaemia. The extension was granted on 29 October 2026. NICE has updated its existing recommendation to cover children aged 5 to 11 and published a managed access agreement, rather than running a separate appraisal. Casgevy is a one-off gene-editing procedure using the patient's own stem cells. It requires conditioning treatment first and a hospital stay afterwards. Side effects include nausea, tiredness, fever and higher infection risk. Approval does not mean instant access. Treatment happens at specialist centres, eligibility criteria apply, and the earlier rollout for over-12s took time. Your child's haematology team is the place to get real answers. Sources: Medicines and Healthcare products Regulatory Agency, "MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders", 30 October 2026, https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders; The Pharmaceutical Journal, "MHRA extends approval for gene-editing therapy to patients aged five years and over", 2026, https://pharmaceutical-journal.com/article/news/mhra-extends-approval-for-gene-editing-therapy-to-patients-aged-five-years-and-over; PharmaTimes, "Vertex wins MHRA backing for wider Casgevy use", 2026, https://pharmatimes.com/news/vertex-wins-mhra-backing-for-wider-casgevy-use/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.

#sickle cell disease#beta-thalassaemia#gene editing#MHRA#NICE#childrens health

Related articles